Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Copy-number variations in multiple myeloma

Published byDamian Green Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Copy-number variations in multiple myeloma"— Presentation transcript:

1 Figure 2 Copy-number variations in multiple myeloma
Figure 2 | Copy-number variations in multiple myeloma. a | Data provided are the average frequencies of recurrent chromosomal gain and loss reported in two studies in which single-nucleotide polymorphism (SNP) arrays were used to analyse samples from 114 (Ref. 55) and 192 (Ref. 76) patients with multiple myeloma. b | Frequency of focal changes in multiple myeloma. Data were obtained from a study using the GISTIC algorithm89 to analyse samples from 153 patients6. CNVs, copy-number variations. Manier, S. et al. (2016) Genomic complexity of multiple myeloma and its clinical implications Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 2 Copy-number variations in multiple myeloma"

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Identification of mucinous carcinoma

Figure 5 Identification of mucinous carcinoma
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway
Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Similar presentations

Ads by Google